On paper, Medicare’s temporary GLP-1 Bridge has attracted substantial demand. At an October 7, 2026, event, federal health official Chris Klomp said approximately 1.1 million Medicare beneficiaries had signed up for access to discounted obesity medications. Under the program, eligible patients can obtain selected versions of Zepbound, Foundayo or Wegovy for a flat $50 monthly copayment.
But enrollment is not the same as receiving medicine. A figure of approximately 700,000 people who had filled prescriptions was reported by Eli Lilly CEO Dave Ricks weeks before the 1.1 million sign-up announcement, according to a November 8 Forbes analysis by health policy writer Joshua P. Cohen.
Those two figures are being compared as though they describe the same moment. They do not. The difference may reflect enrollment growth between reporting dates, administrative delays or a combination of factors. Without a synchronized count, it is impossible to say how many approved beneficiaries have yet to fill a prescription.
Meanwhile, a separate study highlighted by the USC Schaeffer Center on November 6 found that traditional Medicare Part D plans rarely offered coverage of Wegovy or Zepbound for other FDA-approved uses, and Medicare Advantage coverage remained exceptionally limited.
The two developments expose a larger problem. Medicare has built a temporary way around its normal restrictions on obesity drugs, but the permanent insurance system has shown little appetite for paying for them.
The Medicare GLP-1 Bridge has demonstrated demand for lower-cost access. Whether that access survives beyond December 2027 is a different question.
How the Medicare GLP-1 Bridge Works
The Medicare GLP-1 Bridge began on July 1, 2026, as a demonstration administered by the Centers for Medicare & Medicaid Services. It is scheduled to operate through December 31, 2027.
The program provides eligible Medicare beneficiaries access to certain FDA-approved weight-management medications for a $50 monthly copayment. Covered products include Foundayo tablets, Wegovy injections and tablets, and the KwikPen formulation of Zepbound. Other Zepbound presentations, including single-dose pens and vials, are not included.
Although participants must have qualifying Medicare Part D prescription drug coverage, the Bridge operates outside the regular Part D payment system.
That distinction matters. Part D plans do not bear the usual financial risk for medications dispensed through the demonstration, and beneficiaries do not need their individual plans to opt into the Bridge.
The manufacturers provide eligible monthly drug supplies at a net price of $245. After the patient’s $50 copayment, the federal contribution toward that negotiated drug price is $195, apart from other potential program and dispensing expenses.
The $50 copayment does not count toward a beneficiary’s regular Part D deductible or true out-of-pocket spending threshold. Part D low-income subsidies also do not reduce the Bridge copayment.
Eligibility is narrower than simply having obesity or being prescribed a weight-loss drug.
According to CMS, beneficiaries must be at least 18 years old and meet one of three clinical pathways at the time they started GLP-1 therapy.
The first is a body mass index of at least 35. The second is a BMI of at least 30 alongside heart failure with preserved ejection fraction, uncontrolled hypertension or chronic kidney disease at stage 3a or above.
The third is a BMI of at least 27 alongside prediabetes, a previous heart attack, a previous stroke or symptomatic peripheral artery disease.
Additional restrictions apply. Beneficiaries with type 2 diabetes, moderate-to-severe obstructive sleep apnea or qualifying metabolic dysfunction-associated steatohepatitis, known as MASH, are excluded because these conditions can support coverage through ordinary Part D rules.
Someone who has already received a GLP-1 prescription covered by their Part D plan during the relevant lookback period is also generally ineligible for the Bridge.
In a June 2026 analysis using 2023 Medicare records, KFF estimated that approximately 3.8 million beneficiaries met the program’s clinical and insurance requirements. The estimate is not a live count of eligible people in November 2026.
For those who qualify, the $50 price is a considerable reduction from the cash prices patients could otherwise face. But it is available only within a specific, time-limited government demonstration.
What the 1.1 Million Sign-Ups and 700,000 Prescription Fills Actually Show
The enrollment figures deserve closer attention because the apparent gap has become part of the program’s story.
On October 7, HHS official Chris Klomp said roughly 1.1 million Medicare beneficiaries had signed up for the Bridge. Becker’s Payer Issues reported the announcement on October 13.
Separately, Forbes reported that Lilly CEO Dave Ricks had previously shared a figure of approximately 700,000 people who had filled prescriptions through the program.
In its November 8 article, Forbes described the prescription figure as having been shared approximately six weeks earlier. That places it before the October enrollment announcement.
The arithmetic difference is approximately 400,000 people, but that is not an established count of patients waiting for medicine.
Enrollment could have increased substantially after the earlier prescription tally. Some people may also have received authorization but delayed treatment, decided against filling or encountered administrative difficulties.
The available figures do not separate those possibilities.
One figure counts reported sign-ups. The other counts earlier prescription fills. Subtracting them does not establish how many patients were left waiting.
That does not mean problems with access are imaginary. It means the strongest evidence for those problems comes from the program’s procedures and the broader insurance coverage research, rather than from an unmatched pair of headline numbers.
There are also signs the Bridge is drawing people who were not previously receiving GLP-1 treatment. Forbes reported that Walgreens estimated approximately half of its Bridge recipients were new to these medicines.
That supports the argument that a lower copayment can open access to previously untreated patients. It does not tell us how many eligible beneficiaries nationally remain unable to obtain a prescription.
Where the Prescription Process Can Stall
The Bridge operates through a centralized claims-processing system, with Humana serving as the program’s central processor.
A prescriber must determine whether the patient meets the clinical requirements and prescribe an eligible drug for weight management in combination with lifestyle modification.
The pharmacy submits a claim to the Bridge, and an eligibility check establishes whether prior authorization is required. The prescriber then completes the authorization process electronically or by fax.
CMS says a prior authorization decision should be communicated within 72 hours after the completed request is submitted.
Importantly, CMS explicitly states that a pharmacy does not have to obtain a rejection from the patient’s regular Part D plan before submitting an eligible claim directly to the Bridge.
That clarification matters because descriptions of the program as requiring an initial Part D denial can make the process sound more cumbersome than the official instructions actually require.
Even so, several points of friction remain.
A physician may need historical documentation showing that the patient met the BMI criteria when treatment originally began. This can be especially relevant for someone who has already lost weight using a GLP-1 medication purchased outside traditional insurance.
Medical records from cash-pay or telehealth settings may not contain all the information needed for eligibility verification.
Patients also need to complete the prescription and prior authorization process correctly, receive approval, locate a pharmacy able to dispense the covered formulation and pay the copayment.
For lower-income beneficiaries, $50 can remain a meaningful recurring expense, particularly because the program does not apply ordinary Part D low-income cost-sharing assistance.
Once approved, authorization generally remains valid through December 31, 2027, including refills and dose changes, unless the beneficiary switches to a different covered GLP-1 or becomes ineligible.
The program therefore removes one large obstacle, the usual price of the drug, while leaving patients to navigate a separate administrative pathway.
Medicare Advantage Plans Are Still Reluctant to Cover Wegovy and Zepbound
The second piece of the story comes from research by Eunhae Shin of the University of Georgia and Alice Chen of the University of Southern California.
Their research letter, published online in Health Affairs Scholar on October 25, 2026, examined Medicare Part D formulary coverage for non-diabetes GLP-1 therapies between 2024 and 2026. USC highlighted the findings in a November 6 release.
The background is important. Medicare Part D generally excludes drugs when prescribed for weight loss alone, but it can cover medications for other medically accepted FDA-approved uses.
Wegovy received an FDA indication for reducing major cardiovascular events in certain adults in 2024, followed by an indication for MASH with moderate-to-advanced fibrosis in August 2025. Zepbound received an indication for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024.
These additional indications created possible routes to Part D coverage even without a general benefit for weight-loss treatment.
But according to the USC summary, no standalone Part D plan included Wegovy or Zepbound on its formulary during the 2024–2026 study period.
Among beneficiaries enrolled in Medicare Advantage plans, only approximately 1% to 2% had formulary coverage of either drug in a given year.
Coverage was unstable even among the small number of plans offering it.
Of beneficiaries whose plans provided coverage in 2024, only 42% retained that coverage in 2025. Among those with coverage in 2025, just 16% retained it in 2026.
No Medicare Advantage plan in the study maintained coverage of the drugs across all three years.
The researchers reported that most beneficiaries who lost coverage did so because plans removed the medicines from their formularies, rather than because their plans disappeared.
They also found little evidence that plans offering coverage were disproportionately attracting beneficiaries with greater health needs.
The conclusion is narrower than saying nobody with Medicare can obtain these medicines. Formulary inclusion is not the only route to coverage, and the study does not directly measure every approved claim, formulary exception or filled prescription.
Still, the findings show that additional FDA-approved indications have not translated into stable, broad formulary access.
For patients who qualify for a GLP-1 because of cardiovascular risk, sleep apnea or advanced liver disease, the regulatory label may open a legal route to coverage without guaranteeing that a particular plan makes the drug easy to obtain.
FDA approval can make a drug eligible for Medicare coverage. It does not force every prescription drug plan to place that medicine on its formulary.
BALANCE Was Paused, and the Financial Question Remains
The Bridge was not initially intended to be the whole long-term answer.
CMS had also developed a voluntary demonstration known as BALANCE, short for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth.
The model was designed to explore longer-term coverage arrangements for GLP-1 medicines, including participation by Medicare prescription drug plans and Medicaid programs.
But the Medicare portion did not attract sufficient insurer participation to launch on the planned schedule.
Forbes reported that the agency failed to reach its target of participation by at least 80% of Part D plan sponsors. CMS subsequently paused the Medicare model and extended the Bridge through December 2027.
The Medicaid component of BALANCE is proceeding separately.
For Medicare, the central question is who pays for a permanent expansion of access.
KFF’s June 2026 analysis estimated that the federal cost of the 18-month Bridge would be approximately $1.3 billion to $3.3 billion if 10% to 25% of its estimated 3.8 million eligible beneficiaries participated from the beginning and filled a prescription every month.
At participation levels of 50% to 75% under the same assumptions, KFF estimated an 18-month federal cost of approximately $6.7 billion to $10 billion.
These are modeled scenarios, not observed spending totals. Actual costs depend on how many beneficiaries participate, how quickly they start, how long they remain in treatment and how many prescriptions are filled.
It is also important not to mistake the KFF estimate for a prediction that every eligible patient will enroll or remain on treatment for the entire demonstration.
Obesity medicines can produce substantial health benefits in appropriate patients, but the size and timing of any resulting Medicare savings depend on clinical outcomes, persistence and the costs of treatment.
Even negotiated drug prices become expensive when multiplied across millions of potential patients and repeated monthly treatment.
That helps explain why insurers may hesitate to assume financial responsibility for broader coverage, even as demand grows.
The challenge is not unique to Medicare. Grey Pepper has covered how manufacturers and telehealth platforms are competing for self-pay patients in the Wegovy pill versus Foundayo market, and how federal pricing mechanisms influence pharmaceutical costs in our analysis of Medicare drug price negotiation.
The Bridge demonstrates what happens when the patient-facing price is sharply reduced. The unresolved question is how to finance that arrangement after the demonstration ends.
What Happens When the Medicare GLP-1 Bridge Ends in 2027?
The current end date is December 31, 2027.
Unless policymakers extend the demonstration or establish another coverage pathway, beneficiaries who receive weight-management drugs through the Bridge could lose access to its $50 monthly copayment beginning in January 2028.
That does not mean every patient’s medication will automatically disappear. Some may qualify under other insurance coverage, assistance arrangements or future policy changes. Others may face substantially higher costs or interruptions in treatment.
The distinction matters because obesity treatment often requires sustained medication use. A temporary subsidy can make it possible to begin therapy without establishing how patients will afford continued treatment once the subsidy expires.
The immediate evidence gap is straightforward. CMS has not supplied, in the public sources reviewed here, a synchronized national breakdown of enrollment approvals, unique patients who obtained a first fill, rejected claims and people who discontinued treatment.
Such data would help distinguish an administrative access problem from a reporting-timing problem. They would also show whether people enrolling through the Bridge are continuing therapy or receiving only one or two prescriptions.
Another question is whether Medicare Advantage and standalone Part D plans will expand formulary coverage for the drugs’ other FDA-approved indications.
The USC study suggests those plans have so far been reluctant to do so, even when a medication has uses beyond weight reduction.
Policymakers could extend the Bridge, revive a version of BALANCE, modify Medicare’s statutory restrictions or establish another funding arrangement. None of those outcomes is guaranteed by the current program.
The Bridge has already established that large numbers of beneficiaries are interested in obtaining obesity medicines at $50 a month. The available figures also show meaningful early dispensing activity.
What remains uncertain is whether the program can translate that demand into sustained access, and whether the normal insurance system will be prepared to take over.
The most important number in the Medicare GLP-1 Bridge story may eventually be neither 1.1 million sign-ups nor 700,000 earlier fills.
It may be the number of patients still receiving affordable treatment on January 1, 2028.
Medicare has built a temporary bridge to lower-cost GLP-1 treatment. The question is whether there will be a permanent road on the other side.
Sources and Further Reading
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge: Official Program Overview and FAQs, 2026.
- CMS. Medicare GLP-1 Bridge: Information for Part D Plans, including eligibility and payment rules.
- CMS. Medicare GLP-1 Bridge: Information for Pharmacies, prior authorization and prescription processing.
- Medicare.gov. Weight-Loss Drugs: Medicare GLP-1 Bridge Coverage and Eligibility.
- Joshua P. Cohen. Medicare’s Bridge Weight Loss Program Off To Good Start, But Challenges Remain. Forbes, November 8, 2026, updated November 9.
- Becker’s Payer Issues. 1.1 Million Medicare Beneficiaries Signed Up for GLP-1 Bridge Model, October 13, 2026.
- Shin E, Chen A. Persistence and Geographic Availability of Medicare Part D Coverage for Non-Diabetes GLP-1 Therapies, 2024–2026. Health Affairs Scholar, published online October 25, 2026.
- USC Schaeffer Center. Medicare Plans Rarely Cover Anti-Obesity Drugs for Other FDA-Approved Purposes, November 6, 2026.
- KFF. Nearly Four Million Medicare Beneficiaries Met the Eligibility Criteria in 2023 for the Medicare GLP-1 Bridge, June 29, 2026.
